首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1608707

失智症藥物市場：按藥物類別、按適應症、按給藥途徑、按分銷管道、按地區

Dementia Drugs Market, By Drug Class, By Indication, By Route of Administration, By Distribution Channel,By Geography

出版日期: 2024年11月05日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

失智症治療市場預計到2024年將達到244.7億美元，預計到2031年將達到383.3億美元，2024年至2031年的複合年成長率為6.6%。

分析範圍		分析詳情
基準年	2023年	市場規模（2024年）	244.7億美元
實際資料	2019-2023	預測期	2024-2031
預測期複合年成長率（2024-2031）：	6.60%	預計金額（2031年）	383.3億美元

圖：2024年失智症治療藥物的市場佔有率（%），依地區分類

失智症治療藥物市場的成長是由全球阿茲海默症和其他失智症患者數量的增加所推動的。失智症是一種由影響大腦的疾病引起的症候群，例如阿茲海默症或中風。失智症的特徵是思考、記憶和推理等認知功能逐漸喪失。由於人們對失智症診斷和治療方法的認知不斷提高，越來越多的人正在尋求針對失智症症症狀的醫療協助。一些製藥公司正在大力投資研究和開發有效藥物，以減緩或阻止失智症的進展。

市場動態

失智症治療市場的成長主要是由全球人口的快速老化所推動的，這增加了神經退化性疾病的風險。開發中國家不斷成長的醫療保健支出和生物製藥公司的密集研發工作進一步促進了市場擴張。然而，高昂的藥物開發成本是一個重大挑戰，特別是由於許多候選分子在後期臨床試驗中失敗以及這些疾病的複雜性。最近核准的緩解疾病藥物旨在影響疾病發病機制，而不是簡單地緩解症狀，這對製造商來說是一個重大機會。政府對失智症研究的支持和資助的增加正在鼓勵市場參與企業創新和開發新的治療方法。由於人口變化，失智症盛行率持續上升，對有效治療方法的需求預計將成長，市場預計將取得重大進展。

本研究的主要特點

本報告對全球失智症治療藥物市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、關鍵績效和策略等參數，對全球失智症藥物市場的主要企業進行概況分析。

主要企業包括Biogen、 Eisai、Novartis、Cipla、H. Lundbeck、Otsuka Pharmaceutical、Sun Pharmaceutical Industries、Viatris、Mapipharma、AbbVie、Daiichi Sankyo、F. Hoffmann La Roche等將亮相。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球失智症治療藥物市場報告針對該行業的各個相關人員相關者，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

相關人員可以透過用於分析全球失智症治療藥物市場的各種策略矩陣來促進他們的決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	24.47 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	6.60%	2031 Value Projection:	38.33 Bn

Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.

Market Dynamics

Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.

Key features of the study

This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Market Segmentation

By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
- MAO Inhibitors
- Cholinesterase Inhibitors
- Glutamate Inhibitor
- Others
By Indication Insights (Revenue, USD Bn, 2019 - 2031)
- Alzheimer's Disease Dementia
- Lewy Body Dementia
- Parkinson Disease Dementia
- Others
By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Intravenous
- Others
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Biogen
- Eisai Co., Ltd.
- Novartis AG
- Cipla
- Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Mapi-Pharma Ltd.
- AbbVie, Inc.
- DAIICHI SANKYO COMPANY, LIMITED.
- F.Hoffmann-La Roche Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Dementia Drugs Market, By Drug Class
- Dementia Drugs Market, By Indication
- Dementia Drugs Market, By Route of Administration
- Dementia Drugs Market, By Distribution Channel
- Dementia Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Epidemiology
Pipeline Analysis

4. Dementia Drugs Market, By Drug Class, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
MAO Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cholinesterase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Glutamate Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Dementia Drugs Market, By Indication, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Alzheimer's Disease Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Lewy Body Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Parkinson Disease Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Dementia Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Dementia Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Dementia Drugs Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Mapi-Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie, Inc.
DAIICHI SANKYO COMPANY, LIMITED.
Hoffmann-La Roche Ltd